Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Curren...( Program will build on other successf...)

Program will build on other successful GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] patient programs pioneered by Baxter

DEERFIELD, Ill., Aug. 22 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) today announced that it will launch GARDian, an innovative program that helps provide continued access for patients relying on GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (IGIV). IGIV products like GAMMAGARD LIQUID and GAMMAGARD S/D are immunoglobulin (IgG) replacement therapies containing broad-spectrum immunoglobulins and are indicated for patients with primary immunodeficiency. Primary immunodeficiency is a group of genetic disorders in which the immune system fails to produce adequate amounts of antibodies, thereby predisposing individuals to increased risk of infection.

IGIV users and physicians can experience changes involving their providers or site of care that can sometimes impede access to their preferred IGIV therapy. Baxter's GARDian program, which is expected to start early next year, will provide patients and physicians with continued access to GAMMAGARD LIQUID and GAMMAGARD S/D even when such changes occur.

GARDian is viewed as a logical extension of other successful patient- centric programs pioneered by Baxter. The hallmark of each of these programs is continued access to GAMMAGARD LIQUID and GAMMAGARD S/D. They include:

-- GAMMAssist -- An innovative program that allows eligible users of

GAMMAGARD to continue to receive their immunoglobulin therapy in the

event of a lapse in insurance.

-- Low IgA/Brand Intolerance Program -- A program providing patient access

to GAMMAGARD S/D selected
'/>"/>